50,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company’s stock, valued at approximately $1,079,000.

Several other large investors also recently modified their holdings of VRDN. Farther Finance Advisors LLC raised its holdings in shares of Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares during the period. Sei Investments Co. purchased a new stake in Viridian Therapeutics in the second quarter worth $147,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Viridian Therapeutics in the second quarter valued at $170,000. Creative Planning bought a new stake in shares of Viridian Therapeutics in the second quarter valued at $179,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Viridian Therapeutics during the 2nd quarter valued at $180,000.

Analyst Ratings Changes

VRDN has been the subject of several recent research reports. Truist Financial set a $41.00 price objective on Viridian Therapeutics in a report on Monday, November 24th. Royal Bank Of Canada upped their price objective on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, October 8th. BTIG Research reissued a “buy” rating and issued a $61.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, November 4th. Finally, Wedbush upped their price target on shares of Viridian Therapeutics from $42.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.75.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $31.54 on Tuesday. The company has a 50 day moving average of $29.06 and a 200 day moving average of $22.01. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.07. The stock has a market cap of $3.01 billion, a P/E ratio of -10.44 and a beta of 0.86. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $34.04.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The business had revenue of $70.57 million for the quarter, compared to analysts’ expectations of $16.21 million. Viridian Therapeutics’s quarterly revenue was up 81993.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Insider Activity

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 454,545 shares of the company’s stock in a transaction that occurred on Thursday, October 23rd. The stock was bought at an average price of $22.00 per share, with a total value of $9,999,990.00. Following the completion of the purchase, the director owned 3,914,458 shares of the company’s stock, valued at approximately $86,118,076. This represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.65% of the company’s stock.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.